Safe and effective medicines for children : studies conducted under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act /
"The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and P...
Clasificación: | Libro Electrónico |
---|---|
Autores Corporativos: | , |
Otros Autores: | , |
Formato: | Electrónico eBook |
Idioma: | Inglés |
Publicado: |
Washington, D.C. :
National Academies Press,
2012.
|
Temas: | |
Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Introduction
- Children's growth and development and pediatric drug studies
- Policy framework for BPCA and PREA
- Ethical issues in pediatric drug studies
- Safety and efficacy assessment in studies conducted under BPCA and PREA
- BPCA, PREA, and drug studies with neonates
- Outcomes of written requests, requirements, studies, and labelling changes
- Pediatric studies of biologics.